Avesthagen-CIPLA JV Acquires Biological Company in Germany
Avesta Biotherapeutics and Research Pvt. Ltd., a joint venture between Avesthagen and Meditab Specialities Ltd (of Cipla group), announced the acquisition of Siegfried Biologics GmbH, a fully owned subsidiary of the Siegfried Group in Switzerland.
ABRPL, based in Bangalore, will manufacture a series of biopharmaceuticals for the global markets with an initial focus on the BRIC markets. This acquisition fits into the strategy of being able to manufacture under USFDA and EMEA compliant conditions. The facility is expected to initially focus on biopharmaceuticals that are presently under development at Avesthagen through the Avesthagen-Cipla joint venture agreement that was signed in May 2004.
Siegfried Biologics GmbH, based in Berlin, Germany, was started 10 years ago as a contract manufacturing organization (CMO). The 50 plus team of people has a solid background and extensive experience in the development of biologics from cell line generation, upstream process development and scale-up to GMP manufacturing.
According to the company, this acquisition will add process development and GMP manufacturing capabilities to the technology development prowess of Avesthagen and Cipla's marketing expertise to further strengthen ABRPL's impact on a market presently dominated by small chemical entities. The Indian biopharmaceutical business, presently estimated at $1.5 billion, is expected to grow to about $5 billion by 2010, dominated by recombinant proteins, vaccines and monoclonal antibodies.
Other news from the department business & finance
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.
Most read news
More news from our other portals
See the theme worlds for related content
Topic world Antibodies
Antibodies are specialized molecules of our immune system that can specifically recognize and neutralize pathogens or foreign substances. Antibody research in biotech and pharma has recognized this natural defense potential and is working intensively to make it therapeutically useful. From monoclonal antibodies used against cancer or autoimmune diseases to antibody-drug conjugates that specifically transport drugs to disease cells - the possibilities are enormous
Topic world Antibodies
Antibodies are specialized molecules of our immune system that can specifically recognize and neutralize pathogens or foreign substances. Antibody research in biotech and pharma has recognized this natural defense potential and is working intensively to make it therapeutically useful. From monoclonal antibodies used against cancer or autoimmune diseases to antibody-drug conjugates that specifically transport drugs to disease cells - the possibilities are enormous
Topic world biopharmaceutical manufacturing
Biopharmaceutical production plays a crucial role in the development and manufacture of biologics, which are essential for the treatment of various serious diseases. Various key technologies and processes of the modern biopharmaceutical industry are used, such as cell cultures, fermentation processes and the purification of biological substances, which are necessary for the production of vaccines, monoclonal antibodies and other biological drugs.
Topic world biopharmaceutical manufacturing
Biopharmaceutical production plays a crucial role in the development and manufacture of biologics, which are essential for the treatment of various serious diseases. Various key technologies and processes of the modern biopharmaceutical industry are used, such as cell cultures, fermentation processes and the purification of biological substances, which are necessary for the production of vaccines, monoclonal antibodies and other biological drugs.
